CASI Pharmaceuticals, Inc.
CASI
$1.94
$0.22713.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.36M | 7.79M | 3.98M | 3.41M | 6.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.36M | 7.79M | 3.98M | 3.41M | 6.87M |
| Cost of Revenue | 10.13M | 3.75M | 1.91M | 1.60M | 2.82M |
| Gross Profit | 3.23M | 4.05M | 2.07M | 1.81M | 4.06M |
| SG&A Expenses | 11.92M | 10.61M | 10.37M | 8.55M | 11.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.00K | -- | -- | -- | -5.06M |
| Total Operating Expenses | 25.71M | 15.88M | 13.53M | 12.63M | 11.64M |
| Operating Income | -12.35M | -8.09M | -9.55M | -9.22M | -4.77M |
| Income Before Tax | -14.37M | -8.40M | -6.96M | -9.53M | -5.89M |
| Income Tax Expenses | -- | -- | -- | -- | -1.00K |
| Earnings from Continuing Operations | -14.37M | -8.40M | -6.96M | -9.53M | -5.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -163.00K |
| Net Income | -14.37M | -8.40M | -6.96M | -9.53M | -6.06M |
| EBIT | -12.35M | -8.09M | -9.55M | -9.22M | -4.77M |
| EBITDA | -11.77M | -7.15M | -8.62M | -8.28M | -3.83M |
| EPS Basic | -0.75 | -0.55 | -0.52 | -0.71 | -0.45 |
| Normalized Basic EPS | -0.40 | -0.39 | -0.43 | -0.44 | -0.22 |
| EPS Diluted | -0.75 | -0.55 | -0.52 | -0.71 | -0.46 |
| Normalized Diluted EPS | -0.40 | -0.39 | -0.43 | -0.44 | -0.22 |
| Average Basic Shares Outstanding | 19.15M | 15.29M | 13.52M | 13.38M | 13.38M |
| Average Diluted Shares Outstanding | 19.15M | 15.29M | 13.52M | 13.38M | 13.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |